Showing 1 posts of 1 posts found.
The R&D Scoreboard is fundamentally flawed as a measure of R&D investment in the UK and pharmaceutical companies are continuing …
Long-acting therapies set to reshape HIV treatment market
MHRA authorises Lynkuet for hot flushes linked to breast cancer therapy
MHRA approves Romvimza for tenosynovial giant cell tumour
NICE recommends allergy immunotherapy tablets for younger children
Dunbar Pharmaceuticals and IPS Pharma announce distribution agreement